1 / 82

Philippines HIV Therapeutics Market Analysis Sample Report

By 2030, it is anticipated that the Philippines HIV therapeutics market will reach a value of $xx Mn from $30.27 Mn in 2022, growing at a CAGR of xx% during 2022-2030. The market is primarily dominated by local players such as Watson's Personal Care Stores, Mercury Drug Corporation, and United Laboratories. The market is driven by government initiatives, the prevalence of HIV infections, and treatment for HIV. To get a detailed report, contact us at - info@insights10.com

Insights4
Download Presentation

Philippines HIV Therapeutics Market Analysis Sample Report

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. A sample report on Philippines HIV Therapeutics Market Analysis Includes Market Size, Market Segmented by Types and Key Competitors (Data forecasts from 2022 – 2030F) www.insights10.com

  2. This report presents a strategic analysis of the Philippines HIV Therapeutics Market and a forecast for its development in the medium and long term. It provides a comprehensive overview of the market value, dynamics, segmentation, types of clinical diagnostics, point-of-care testing, main players, growth and demand drivers, challenges & future outlook, etc. This is one of the most comprehensive reports about the Philippines HIV Therapeutics Market, and offers unmatched value, accuracy, and expert insights

  3. Report Scope Report Attribute Details Number of Pages 70-80 Base Year for Estimation 2022 Forecast Period 2023-2030 Market Overview, Revenue Forecast, Market Segmentation, Growth Factors and Trends, Competitive Landscape, Key Company Profiles, Government Policies, Regulatory Landscape, Reimbursement Scenario Report Coverage Quantitative Units Revenue in USD Million/Billion (Mn/Bn) Research Approach Secondary Research (60%), Primary Research (40%) Click on the icon to know the detailed methodology 3 A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential

  4. Table of Content CONTENT PG. NO. 12-25 1. HIV Therapeutics Overview 1.1. Overview 1.2. Philippines Overview 1.3. Economic Overview: Philippines 1.4. HIV Therapeutics Market in Philippines 1.5. Pharmaceuticals Market in Philippines 1.6. Healthcare Scenario in Philippines 1.7. Health Insurance Coverage: Philippines 1.8. Budget of the Government for Public Insurance 1.9. Mergers and Acquisitions 26-33 2. Market Size and Forecasting 2.1 Market size and forecasts (Excel and Methodology) 4 A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential

  5. Table of Content CONTENT PG. NO. 2.2. Market Segmentation 2.2.1 Types 2.2.2. Distribution Channel 34-38 3. Market Dynamics 3.1. Market Growth Drivers 3.1.1. Philippines HIV Therapeutics Market Driver 1 3.1.2. Philippines HIV Therapeutics Market Driver 2 3.1.3. Philippines HIV Therapeutics Market Driver 3 3.2. Market Restraints 3.2.1. Philippines HIV Therapeutics Market Restraint 1 3.2.2. Philippines HIV Therapeutics Market Restraint 2 5 A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential

  6. Table of Content CONTENT PG. NO. 3.2.3. Philippines HIV Therapeutics Market Restraint 3 39-49 4. Competitive Landscape 4.1. Major Market Share 4.2. Key Company Profile 4.2.1. Gilead Sciences 4.2.1.1. Overview 4.2.1.2. Product Applications & Services 4.2.1.3. Recent Developments 4.2.1.4. Partnerships Ecosystem 4.2.1.5. Financials (Based on Availability) 4.2.2. Merck 4.2.2.1. Overview 6 A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential

  7. Table of Content CONTENT PG. NO. 4.2.2.2. Product Applications & Services 4.2.2.3. Recent Developments 4.2.2.4. Partnerships Ecosystem 4.2.2.5. Financials (Based on Availability) 4.2.3. Pfizer 4.2.3.1. Overview 4.2.3.2. Product Applications & Services 4.2.3.3. Recent Developments 4.2.3.4. Partnerships Ecosystem 4.2.3.5. Financials (Based on Availability) 4.2.4. AstraZeneca 4.2.4.1. Overview 7 A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential

  8. Table of Content CONTENT PG. NO. 4.2.4.2. Product Applications & Services 4.2.4.3. Recent Developments 4.2.4.4. Partnerships Ecosystem 4.2.4.5. Financials (Based on Availability) 4.2.5. United Laboratories 4.2.5.1. Overview 4.2.5.2. Product Applications & Services 4.2.5.3. Recent Developments 4.2.5.4. Partnerships Ecosystem 4.2.5.5. Financials (Based on Availability) 4.2.6. Mercury Drug Corporation 4.2.6.1. Overview 8 A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential

  9. Table of Content CONTENT PG. NO. 4.2.6.2. Product Applications & Services 4.2.6.3. Recent Developments 4.2.6.4. Partnerships Ecosystem 4.2.6.5. Financials (Based on Availability) 4.2.7. Novartis 4.2.7.1. Overview 4.2.7.2. Product Applications & Services 4.2.7.3. Recent Developments 4.2.7.4. Partnerships Ecosystem 4.2.7.5. Financials (Based on Availability) 4.2.8. GlaxoSmithKline 4.2.8.1. Overview 9 A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential

  10. Table of Content CONTENT PG. NO. 4.2.8.2. Product Applications & Services 4.2.8.3. Recent Developments 4.2.8.4. Partnerships Ecosystem 4.2.8.5. Financials (Based on Availability) 4.2.9. Johnson & Johnson 4.2.9.1. Overview 4.2.9.2. Product Applications & Services 4.2.9.3. Recent Developments 4.2.9.4. Partnerships Ecosystem 4.2.9.5. Financials (Based on Availability) 4.2.10. ViiV Healthcare 4.2.10.1. Overview 10 A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential

  11. Table of Content CONTENT PG. NO. 4.2.10.2. Product Applications & Services 4.2.10.3. Recent Developments 4.2.10.4. Partnerships Ecosystem 4.2.10.5. Financials (Based on Availability) 50-57 5. Reimbursement Scenario 5.1. Reimbursement Regulation 5.2. Reimbursement Process for Diagnosis 5.3. Reimbursement Process for Treatment 58-63 6. Methodology & Scope 11 A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential

  12. Philippines HIV Therapeutics Market Analysis 1. HIV Therapeutics Overview

  13. 1.1 Statistics at a Glance: The Burden of HIV in the World Prevalence of HIV Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ 38.4 Mn are living with HIV worldwide 0.7% of people aged between 15– 49 years worldwide are living with HIV In this section you will get an understanding of the topic, which includes the prevalence of the disease, the application of medical devices, new technology, and other details related to the topic ▪ 1 in 25 adults in African region are affected by HIV 650,000 people died of HIV-related illnesses worldwide in 2021 In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 90 low- and middle-income countries reported a total of 190 million people tested and received results in 2020 160,000 children have acquired HIV in 2021 13 A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential

  14. 1.1 Statistics at a Glance: The Burden of HIV in the World (continued) Europe ~Revenue to reach $XX Bn by 2027 North America ~ Market Size of $XX Bn Asia -Fastest CAGR Africa Philippines Market ~$XX Mn Market ~Market Size of $XX Bn Illustrative Illustrative 14 A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential

  15. 1.2 Philippines Overview Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ In this section you will get an understanding of the demographics of the country/region, which includes the population, GDP, healthcare expenditure and other details related to the topic ▪ 111 Mn Is the population of Philippines, in 2021 $394 Mn Is the Gross Domestic Product (GDP) in Philippines in 2021 In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 30 Is the median age in Philippines, in 2022 $175 per capita was the amount of national health expenditures in 2021 15 A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential

  16. 1.3 Economic Overview: Philippines Population of Philippines, (2020-2030) GDP of Philippines, (2020-2030) XX XX XX XX 2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2023F 2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2023F Population Split (2023) In this section you will get an understanding of the demographics of the country/region, which includes the population, GDP, healthcare expenditure and other details related to the topic ▪ By Gender By Age Group In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ 0-14 15-24 25-54 Male 49% Female 51% Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 55-64 65+ Illustrative Illustrative 16 A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential

  17. 1.4 Statistics at a Glance: The Burden of HIV in Philippines Prevalence of HIV Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ 21% higher cases were detected in 2022 than 2021 41 cases of HIV were detected in 2022 as compared to 34 in 2021 In this section you will get an understanding of the topic, which includes the prevalence of the disease, the application of medical devices, new technology, and other details related to the topic in Philippines ▪ 14,970 new HIV cases detected between January and December 2022 4,377 people diagnosed with acquired immunodeficiency syndrome in 2022 In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ 14,637 cases were due to sexual contact 95 HIV infections were acquired through sharing of infected needles Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 17 A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential

  18. 1.5 Pharmaceuticals in Philippines Philippines Pharmaceuticals Market Forecast, 2022-2030 (in $Bn) XX 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ In this section you will get an understanding of the overall Pharmaceuticals market in Philippines, which includes the market size, current trends and other details related to the topic ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Illustrative Illustrative 18 A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential

  19. 1.6 Healthcare Scenario in Philippines HIV Therapeutics Drug Development Process: The process of developing a HIV Therapeutics drug is complex and involves many stages, from preclinical research to clinical trials to regulatory approval. Here is a simplified diagram of the HIV Therapeutics drug development process: Preclinical Research: Researchers identify potential drug candidates and test them in the lab Phase 1 Clinical Trials: Small studies are conducted to test the safety and dosage of the drug in humans Phase 2 Clinical Trials: Larger studies are conducted to test the effectiveness of the drug in treating HIV Therapeutics Phase 3 Clinical Trials: Even larger studies are conducted to compare the new drug to standard treatments and evaluate its safety and effectiveness Regulatory Approval: The drug is reviewed by regulatory agencies such as the FDA and approved for use in the US market o o o o o FDA has developed several approaches to making drugs available as quickly as possible, while still ensuring their safety and effectiveness. Here are four of these approaches: Fast track is a process designed to facilitate the development, and expedite the review of drugs to treat serious conditions and fill an unmet medical need ▪ Fast Track A process designed to expedite the development and review of drugs which may demonstrate substantial improvement over available therapy Breakthrough Therapy ▪ These regulations allowed drugs for serious conditions that filled an unmet medical need to be approved based on a surrogate endpoint Accelerated Approval ▪ Priority Review A Priority Review designation means FDA’s goal is to take action on an application within 6 months ▪ Illustrative Illustrative 19 A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential

  20. 1.6 Healthcare Scenario: HIV/AIDS Patient Journey Presentation Diagnosis Treatment Follow up Confirmatory Diagnosis Complete blood count (evaluate number & quality of RBCs, Hb & WBCs) Prevention and management of crisis: • For VOC and Splenic Sequestration: HU, Endari, Adakveo, Oxbryta • For infections: Antibiotics, Vaccines • Long term follow-up is required for patients with SCD • Annual assessment: CBC and reticulocyte count, iron status, liver and renal function tests, urinalysis, LDH, vitamin D level and neurocognitive assessment • ESOD (End Stage Organ Damage) evaluation starting from age 7 • Yearly Transcranial Doppler test to determine risk of stroke Initial Diagnosis Imaging (confirm bone related changes or respiratory problems) A suspected diagnosis is usually made, based on physical examination and detailed patient and family history Prenatal screening/ Neonatal screening Bacterial cultures of blood, sputum, urine, stool (detect any infection) Prevention and management of complications: Genetic testing (detect the type of SCD) • Stroke: Chronic transfusions, HU Stakeholders PCP, pediatrician, neonatologist, endocrinologist, cardiologist, hematologist, orthopedist, psychologist and psychiatrist PCP, paediatrician, neonatologist, haematologist and genetic counsellor PCP, pediatrician, medical geneticist, cardiologist, hematologist, endocrinologist, psychologist and psychiatrist PCP, pediatrician, medical geneticist, hematologist, gynecologist and pathologist Depending on the organ complications, the treatment involves different specialists at different times Illustrative Illustrative 20 A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential

  21. 1.7 Health Insurance Coverage: Philippines % of People by Type of Health Insurance Coverage (2021) Number of People By Health Insurance Coverage Coverage Type 2020 2021 Change % 8.3 Uninsured Total 327,521 328,074 91.7 With health insurance Any health plan 299,230 300,887 0.4 Any private plan 217,896 216,366 –0.6 66.0 Any private plan Employment-based 178,737 178,285 –0.2 54.3 Employment-based Direct-purchase 33,869 33,555 –0.1 10.2 Direct-purchase Marketplace coverage 10,924 11,389 0.1 3.5 Marketplace TRICARE 9,165 8,299 –0.3 2.5 TRICARE Any public plan 112,925 117,095 1.2 Medicare 58,541 60,226 0.5 35.7 Any public plan 18.4 Medicare Medicaid 58,778 61,940 0.9 18.9 Medicaid VA and CHAMPVA 2,967 3,151 0.1 1.0 VA and CHAMPVA Uninsured 28,291 27,187 –0.4 In 2021, most people (91.7%) had health insurance coverage at some point during 2021 and 8.3 % of people were uninsured for the entire calendar year More people had private health insurance (66%) than public coverage (35.7%) Employer-based insurance was the most common subtype of health insurance in the civilian, noninstitutionalized population (54.3%), followed by Medicaid (18.9%), Medicare (18.4%), direct-purchase insurance (10.2%), TRICARE (2.5%), and VA and CHAMPVA health care (1%) ▪ ▪ ▪ Illustrative Illustrative 21 A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential

  22. 1.8 Budget of Philippines Government for Public Insurance Proposed Budget By Category 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2022-31 Outlays $769 $709 $766 $841 $840 $947 $1,014 $1,085 $1,227 $1,178 $1,325 $1,412 $10,633 Medicare In Billions Of Dollars $458 $521 $571 $582 $616 $645 $674 $698 $734 $768 $801 $837 $6,926 Medicaid 3.7% 3.2% 3.3% 3.4% 3.3% 3.6% 3.7% 3.8% 4.1% 3.8% 4.1% 4.2% 3.7% Medicare As % Of GDP 2.2% 2.4% 2.4% 2.4% 2.4% 2.4% 2.4% 2.4% 2.5% 2.5% 2.5% 2.5% 2.4% Medicaid National Health Expenditures (NHE) grew 2.7% to $4.3 trillion in 2021, or $12,914 per person, and accounted for 18.3% of Gross Domestic Product (GDP) ▪ Medicare spending grew 8.4% to $900.8 billion in 2021, or 21% of total NHE ▪ Medicaid spending grew 9.2% to $734.0 billion in 2021, or 17% of total NHE ▪ Private health insurance spending grew 5.8% to $1,211.4 billion in 2021, or 28% of total NHE ▪ Out of pocket spending grew 10.4% to $433.2 billion in 2021, or 10% of total NHE ▪ Other Third Party Payers and Programs and Public Health Activity spending declined 20.7% in 2021 to $596.6 billion, or 14% oftotal NHE ▪ Hospital expenditures grew 4.4% to $1,323.9 billion in 2021, slower than the 6.2% growth in 2020 ▪ Physician and clinical services expenditures grew 5.6% to $864.6 billion in 2021, slower growth than the 6.6% in 2020 ▪ Prescription drug spending increased 7.8% to $378.0 billion in 2021, faster than the 3.7% growth in 2020 ▪ Largest shares of total health spending were sponsored by the federal government (34%) and the households (27%). The private business share of health spending accounted for 17% of total health care spending, state and local governments accounted for 15%, and other private revenues accounted for 7% ▪ Illustrative Illustrative 22 A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential

  23. 1.9 Mergers and Acquisitions RCM M&A Deal Value Trend ($Bn) RCM M&A Deal Volume Trend $16.7 112 110 107 107 89 82 $11.7 $10.5 $7.7 $6.8 $6.0 1H 2020 2H 2020 1H 2021 2H 2021 1H 2022 2H 2022 1H 2020 2H 2020 1H 2021 2H 2021 1H 2022 2H 2022 Buyer Composition: Strategic Vs Financial (2020) Buyer Type by Deal Size ($Mn) 39% 41% 41% 42% 58% 59% 59% 61% Strategic Buyers Financial Buyers $0- $25 $25-$50 $50-$100 $100+ 57% of the total deal volume are done by strategic buyers and the rest 43% are done by financial buyers in 2020 Illustrative Illustrative 23 A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential

  24. 1.9 Mergers and Acquisitions (continued) Latest Deals In Philippines Amount / Duration Company Name Type Year Key Pointers Oracle’s acquisition of Cerner is big tech’s latest foray into the healthcare system, promising better outcomes Oracle acquire Cerner through an all-cash tender offer for $95.00 per share, or approximately $28.3 Bn in equity value Cerner is a leading provider of digital information systems used within hospitals and health systems to enable medical professionals to deliver better healthcare to individual patients and communities ▪ ▪ Acquisition $28.3 Bn June, 2022 ▪ Oracle acquisition of Cerner GSK has acquire BELLUS for US$14.75 per share of common stock in cash representing an approximate total equity value of US$2.0 billion ▪ BELLUS is a late-stage biopharmaceutical company working to better the lives of patients suffering from persistent cough ▪ Acquisition $2 Bn April 2023 Acquisition further strengthens specialty medicines and respiratory pipeline with camlipixant, a highly selective P2X3 antagonist and potential best-in-class treatment for refractory chronic cough ▪ GSK acquisition of BELLUS Health Illustrative Illustrative 24 A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential

  25. 1.9 Mergers and Acquisitions (continued) Latest Deals In Philippines Amount / Duration Company Name Type Year Key Pointers Merger March 2023 Merger Jan 2023 25 A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential

  26. Philippines HIV Therapeutics Market Analysis 2. Market Size and Forecasting

  27. 2.1 Market size and forecasts (Excel and Methodology) Click on the icon to know the methodology and assumption Philippines HIV Therapeutics Market Forecast, 2022-2030 (in $Bn) Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ XX XX In this section you will get an understanding of the overall Healthcare Insurance market in Malaysia, which includes the market size, current trends and other details related to the topic ▪ 2022 2023F 2024F 2025F 2026F 2025 2027F 2026 2028F 2027 2029F 2030F 2023 2024 2028 2029 2030 In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Major Markets Patient (Mn) 2.74 2.82 2.90 2.94 2.98 3.02 3.07 3.12 Philippines Patient Size (Bn) 0.51 0.61 0.68 0.69 0.70 0.71 0.72 0.73 Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest Illustrative Illustrative ▪ % of US Patients 18.75% 21.70% 23.56% 23.45% 23.42% 23.39% 23.34% 23.45% Global Market Size (Bn $) 3,620 3,780 3,950 4,128 4,314 4,508 4,711 4,937 Philippines Market Size (Bn $) 61 74 84 87 91 95 99 106 27 A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential

  28. 2.2 Snapshot of HIV Therapeutics Market Segmentation Types Distribution Channel Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs) Hospital Pharmacies Coreceptor Antagonists Retail Pharmacies Online Pharmacies Entry and Fusion Inhibitors Others Integrase Inhibitors Protease Inhibitors (PIs) Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) In this section you will get an understanding of the segmentations which will cover the Philippines HIV Therapeutics Market ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ 28 A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential

  29. 2.2.1 Market Segmentation: By Types Nucleoside-Analog Reverse Transcriptase Inhibitors market in Philippines is a significant component of the overall HIV therapeutics treatment market ▪ Philippines HIV Therapeutics Market Share, By Types (2022) Non-Nucleoside Reverse Transcriptase … It has the maximum market share in Philippines HIV therapeutics market with approximately xx% ▪ Protease Inhibitors (PIs) Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ Nucleoside- Analog Reverse Transcriptase Inhibitors (NRTIs) Integrase Inhibitors In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Entry and Fusion Inhibitors Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Coreceptor Antagonists 29 A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential

  30. 2.2.2 Market Segmentation: By Distribution Channel Hospital Pharmacies market in Philippines is a significant component of the overall HIV therapeutics market ▪ Philippines HIV Therapeutics Market Share, By Distribution Channel (2022) It has the maximum market share in Philippines HIV therapeutics market with approximately xx% ▪ Others Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ Hospital Pharmacies Online Pharmacies In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Retail Pharmacies 30 A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential

  31. Philippines HIV Therapeutics Market Analysis 3. Market Dynamics

  32. 3.1 Market growth drivers 3.1.1 Incidence of HIV Therapeutics is increasing in Philippines, with more than 1.8 Mn new HIV Therapeutics cases expected to be diagnosed in 2023 Incidence of HIV Therapeutics in Philippines Incidence of HIV Therapeutics is increasing in Philippines, with more than 1.8 Mn new HIV Therapeutics cases expected to be diagnosed in 2023 ▪ This is driving the demand for HIV Therapeutics treatments and creating opportunities for growth in the HIV Therapeutics market ▪ Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 2010 2022 2030 Illustrative Illustrative 32 A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential

  33. 3.1 Market growth drivers (continued) 3.1.2 Death rate from HIV Therapeutics in Philippines has declined by 31% from 1992 to 2022, largely due to advances in technology and treatment options Top countries that are leveraging technology in their fight against HIV Therapeutics Philippines has a long history of investing in HIV Therapeutics research and treatment, and as a result, has become a world leader in the field ▪ Norway IT has a robust healthcare infrastructure, including world- renowned research institutions, hospitals, and clinics, that are dedicated to HIV Therapeutics treatment and research ▪ Austria Denmark Belgium Spain One of the key factors that has allowed Philippines to stay ahead in the field of HIV Therapeutics research and treatment is the high level of investment in HIV Therapeutics-related research ▪ Italy Netherlands Sweden Singapore Switzerland Israel In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Australia Canada France Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ United Kingdom China South Korea Germany Japan United States Illustrative Illustrative 33 A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential

  34. 3.1 Market growth drivers (continued) 3.1.3 In 2021, the National HIV Therapeutics Institute (NCI) received $6.4 Bn in funding from Philippines federal government to support HIV Therapeutics research and training programs Fundings from government and other organizations Philippines government provides significant support and funding for HIV Therapeutics research and treatment, which is driving innovation and growth in the HIV Therapeutics market ▪ Source Year Fund ($) Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ National HIV Therapeutics Institute (NCI) 2021 $ 6.4 Bn In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Centers for Disease Control and Prevention (CDC) 2021 $ 501 Mn Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ American HIV Therapeutics Society (ACS) 2020 $ 150 Mn Susan G. Komen 2020 $ 98 Mn Illustrative Illustrative 34 A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential

  35. 3.2 Market restraints 3.2.1 In 2020, the average cost of a new HIV Therapeutics drug was over $150,000 per year 3.2.2 Average cost of developing a new HIV Therapeutics drug that is ultimately approved by the FDA is over $2.6 Bn 3.2.3 Demand for HIV Therapeutics care is expected to increase by 42% by 2025, while the supply of oncologists is only expected to increase by 28% HIV Therapeutics treatments can be very expensive and can lead to financial burden for patients and healthcare systems Cost of HIV Therapeutics treatment varies depending on the type of HIV Therapeutics, stage of HIV Therapeutics, and treatment options Some common HIV Therapeutics treatments, such as chemotherapy and radiation therapy, can cost tens of thousands of dollars Regulatory requirements for HIV Therapeutics treatments can be very stringent, which can slow down the approval process and limit access to new treatments Regulatory bodies, such as Philippines Food and Drug Administration (FDA), require extensive clinical trials and safety data before approving new HIV Therapeutics treatments This can be a lengthy and costly process, which can delay the availability of new treatments for patients There is a shortage of oncologists in Philippines, which can limit access to HIV Therapeutics treatments and create barriers to growth in the HIV Therapeutics market Oncologists are physicians who specialize in the diagnosis and treatment of HIV Therapeutics With the aging population and the increasing incidence of HIV Therapeutics, there is a growing demand for oncologists However, the supply of oncologists is not keeping pace with the demand Illustrative Illustrative ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ Our analysis will thoroughly investigate the key restraints that may significantly impact business operations and growth. 35 A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential

  36. Philippines HIV Therapeutics Market Analysis 4. Competitive Landscape

  37. 4.1 Major Market Share Revenue of Major players in Philippines HIV Therapeutics Market ($ Mn) Philippines HIV Therapeutics market is a highly competitive space, with many companies developing and marketing HIV Therapeutics treatments ▪ Other Some of the top companies in Philippines HIV Therapeutics market based on revenue and market share include ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ XX Illustrative Illustrative 37 A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential

  38. 4.2 Key Company Profile Key Note: 1 Gilead Sciences Here is the list of top 10 companies which will cover in the final report ▪ 2 Merck Each company will have slides for ▪ 3 Overview Key details Offerings Name of products Recent activities/ Press Coverage Distribution and Vendor Partners Mergers, Acquisitions and Collaboration Financials If there are specific companies that you would like to be included in the report, please let us know via email In order to obtain access to all of the information that you are seeking, you will need to purchase the final report Pfizer o o 4 AstraZeneca o o 5 United Laboratories o Mercury Drug Corporation 6 o o 7 Novartis o 8 GlaxoSmithKline ▪ 9 Johnson & Johnson ▪ 10 ViiV Healthcare 38 A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential

  39. 4.2.1 Gilead Sciences Solutions offered by Gilead Founded in: 1987 ▪ Gilead Sciences is a biopharmaceutical business that conducts research to find, develop, and market novel medications in areas where there is an unmet medical need ▪ It focuses on the discovery and development of antiviral medicines for the treatment of HIV/AIDS ▪ Gilead is pushing innovation that has the potential to become the next generation of life-changing medications via bold and revolutionary research ➢ Therapeutic Areas HQ: California, US ➢ Medicines Type: Private ➢ Pipeline Revenue: $24.6 Mn ➢ Research Website: www.gilead.com ➢ Clinical Trials Drugs for HIV Therapeutics Recent Activity / Press Coverage Drugs Indications With the acquisition of XinThera, Gilead strengthens its early pipeline in oncology and inflammation Biktarvy® Patients weighing atleast 14 Kg Complera® Patients in 12 years and above CHMP Issues Positive Opinion Recommending Hepcludex® (Bulevirtide) for Full Marketing Authorization for Hepatitis Delta Virus (HDV) Treatment Descovy® Patients weighing atleast 35 Kg Emtriva® HIV-1 infection Gilead continues to work to stop the distribution of counterfeit HIV medications and ensure patient safety Genvoya® Patients weighing atleast 25 Kg Odefsey® Patients in 12 years and above 39 A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential

  40. 4.2.1 Gilead Sciences (continued) Partnerships Ecosystem Gilead HIV Age Positively initiative aims to enhance care, offer education, and shape policy for the expanding number of people living with HIV and aging Scholarship provides financing to organizations that serve Black populations affected by triple-negative breast cancer (TNBC) Toward Health Equity Oncology Grant™ (THE Oncology Grant) is an annual effort that catalyzes new methods to improving health equality across the cancer treatment continuum RADIAN is an innovative collaboration between Gilead Sciences and the Elton John AIDS Foundation to address new HIV infections and deaths from HIV-related diseases in Eastern Europe and Central Asia, with the goal of improving the quality of prevention and care for persons at risk of or living with HIV 40 A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential

  41. 4.2.1 Gilead Sciences (continued) Latest Deals - Mergers and Acquisitions Amount / Duration Company Name Type Year Key Pointers This Acquisition expands Gilead's existing clinical development goals by adding pipeline assets for well-validated cancer and inflammatory areas Gilead acquires access to a portfolio of small molecule inhibitors targeting PARP1 in cancer and MK2 in inflammatory illnesses, which might enter clinical trials later this year ▪ Acquisition - May 2023 ▪ Xinthera MiroBio's patented discovery methodology and comprehensive range of immune inhibitory receptor agonists are now available to Gilead ▪ September 2022 Acquisition $405 Mn MB272, MiroBio's primary investigational antibody, is a selective agonist of the immunological suppressive receptors B- and T- Lymphocyte Attenuator (BTLA) that has begun Phase 1 clinical trials ▪ MiroBio 41 A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential

  42. 4.2.1 Gilead Sciences (continued) Revenues ($Bn), 2020-2030 According to Gilead's 2020 financial report, the company had sales of CHF 58.3 Bn (Swiss Francs) in 2020 ▪ This is equivalent to approximately $63.3 Bn USD, based on exchange rates at the end of 2020 ▪ XX Company's Pharmaceuticals Division generated sales of CHF 49.9 Bn in 2020, while the Diagnostics Division generated sales of CHF 8.4 Bn ▪ 2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F Breakdown of Net Revenue by Segment, 2022 Revenue generated by Gilead in 2020 reflects the company's continued growth and success in the healthcare industry ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ 1 2 3 4 Illustrative Illustrative 42 A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential

  43. 4.2.2 Company 2 Solutions offered by Company Founded in: HQ: Type: Revenue: Website: Drugs for HIV Therapeutics Recent Activity / Press Coverage Drugs Indications Illustrative Illustrative 43 A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential

  44. 4.2.2 Company 2 (continued) Partnerships Ecosystem Major Distribution Partners Major Vendor Partners Illustrative Illustrative 44 A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential

  45. 4.2.2 Company 2 (continued) Latest Deals - Mergers and Acquisitions Amount / Duration Company Name Type Year Key Pointers Illustrative Illustrative 45 A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential

  46. 4.2.2 Company 2 (continued) Revenues ($Bn), 2020-2030 Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ xx xx xx In this section you will the understating of financial overview of the company, which includes revenue forecasting, segment revenue and other key details as per availability ▪ 2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Breakdown of Net Revenue by Segment, 2022 Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 1 2 3 4 Illustrative Illustrative 46 A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential

  47. Philippines HIV Therapeutics Market Analysis 5. Reimbursement Scenario

  48. 5.1 Reimbursement Regulation Medicare and Medicaid together provide health insurance coverage for more than 4 in 10 Americans The reimbursement scenario in the US HIV Therapeutics market is complex and can vary depending on the specific treatment, setting of care, and insurance coverage. Here are some key points to consider: Medicare: o ▪ Medicare is a federal health insurance program for people aged 65 and older, as well as people with certain disabilities or health conditions Medicare covers many HIV Therapeutics treatments, including chemotherapy, radiation therapy, and some immunotherapies However, coverage can be subject to strict guidelines and restrictions, such as the requirement for prior authorization Medicaid: o Medicaid is a joint federal-state program that provides health insurance for people with low incomes o Medicaid coverage for HIV Therapeutics treatments can vary by state, and may be subject to limits on the amount and type of treatment covered Private Insurance: o Private insurance coverage for HIV Therapeutics treatments can also vary widely depending on the insurer and the specific policy o Some policies may have high out-of-pocket costs, such as deductibles and co-pays, while others may have more comprehensive coverage Other Public 1% o Other Private 3% Uninsured 9% Medicare 17% o ▪ Medicaid and CHIP 21% ▪ Employer-Sponsored 49% Health Insurance Coverage, 2022 Illustrative Illustrative 48 A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential

  49. 5.1 Reimbursement Regulation (continued) Affordable Care Act: Affordable Care Act (ACA) includes provisions to help improve access to HIV Therapeutics treatments by requiring insurers to cover certain preventive services, including HIV Therapeutics screenings, without co-pays or deductibles It also includes protections for people with pre-existing conditions, such as HIV Therapeutics Reimbursement for New Treatments: Reimbursement for new HIV Therapeutics treatments can be a complex and lengthy process, as insurers and government programs often require evidence of safety and effectiveness before providing coverage This can create challenges for companies developing and marketing new treatments Value-Based Care: There is a growing trend towards value-based care, which aims to improve outcomes and lower costs by focusing on the value of treatments rather than simply the volume of treatments Value-based care models can include payment models that tie reimbursement to outcomes or performance metrics ▪ o o ▪ o o ▪ o o In order to obtain access to all of the information that you are seeking, you will need to purchase the final report Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest Illustrative Illustrative 49 A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential

  50. 5.1 Reimbursement Regulation (continued) Coverage Penetration (% Total Population) Source of Funding Spend on Healthcare (%of Current Health Expenditure) 100% 100% 100% 100% 100% 44.0% Government Expenditure 46.0% xx 47.7% xx xx xx 51.0% 51.8% xx Public Healthcare Coverage Private Health Insurance Out of Pocket 38.9% 37.1% 35.6% 31.5% 32.5% Private Coverage Other NA NA 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023  Public healthcare coverage is provided by the government and includes programs like Medicare and Medicaid  Medicare is a federal program that provides healthcare coverage to individuals who are 65 years of age or older, as well as certain younger people with disabilities  Medicaid is a joint federal-state program that provides healthcare coverage to individuals with low income and limited resources 6.3% 4.08% 5.1% 3.8% 2.2% 2.4% 3.6% GDP Growth (yoy) 14.7% 11.3% 15.5% 7.5% 4.2% NA NA HC Spend Growth (yoy) Reimbursement Market Trends ▪ Shift towards value-based care has been a significant trend in the US healthcare system, with payers and providers increasingly focused on improving patient outcomes and reducing costs ▪ This has led to the development of alternative payment models such as accountable care organizations (ACOs) and bundled payment arrangements, which incentivize providers to deliver high-quality, cost-effective care Illustrative Illustrative 50 A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential

More Related